• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics of high-dose busulfan in children.

作者信息

Vassal G, Gouyette A, Hartmann O, Pico J L, Lemerle J

机构信息

Clinical Pharmacology Unit (URA 158 CNRS, U 140 INSERM), Institut Gustave-Roussy, Villejuif, France.

出版信息

Cancer Chemother Pharmacol. 1989;24(6):386-90. doi: 10.1007/BF00257448.

DOI:10.1007/BF00257448
PMID:2791192
Abstract

The pharmacokinetics of high-dose busulfan given orally at 1 mg/kg every 6 h over 4 days (total dose, 16 mg/kg) in combined chemotherapy followed by autologous bone marrow transplantation was studied in 12 children with a mean age of 7 years (range, 4-14 years). Busulfan levels in biological fluids were measured by a gas chromatographic assay with mass fragmentographic detection, using a deuterated analogue as the internal standard. In a high-dose regimen, busulfan followed one-compartment model kinetics with zero-order absorption. A mean maximal concentration of 803 +/- 228 ng/ml was achieved at 92-255 min after dosing. The mean elimination half-life was 2.33 h, and the mean total clearance was 119 +/- 54 ml/min per m2, with an apparent distribution volume of 27.10 +/- 11.50 l/m2. A mean trough level of 370 ng/ml was found throughout the 4 days of the chemotherapy course. There were no significant variations in pharmacokinetic parameters measured after the first and last doses. Busulfan was monitored in the CSF of nine children at 3.25-7 h after the last dose and was detected in all patients, with a mean CSF-to-plasma concentration ratio of 0.95 (range, 0.5-1.4).

摘要

相似文献

1
Pharmacokinetics of high-dose busulfan in children.
Cancer Chemother Pharmacol. 1989;24(6):386-90. doi: 10.1007/BF00257448.
2
Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation.高剂量白消安在接受骨髓移植的儿科患者中的处置情况。
Clin Pharmacol Ther. 1993 Jul;54(1):45-52. doi: 10.1038/clpt.1993.108.
3
Chronopharmacology of high-dose busulfan in children.儿童高剂量白消安的时辰药理学
Cancer Res. 1993 Apr 1;53(7):1534-7.
4
Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.接受骨髓移植的儿童中白消安的处置与肝静脉闭塞病
Cancer Chemother Pharmacol. 1996;37(3):247-53. doi: 10.1007/BF00688324.
5
Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.接受静脉注射白消安进行异基因造血干细胞移植的婴幼儿的药代动力学特征及临床结局
Biol Blood Marrow Transplant. 2007 Mar;13(3):307-14. doi: 10.1016/j.bbmt.2006.10.026.
6
Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.
Cancer Res. 1990 Oct 1;50(19):6203-7.
7
Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation.
Pediatr Transplant. 2003;7 Suppl 3:12-8. doi: 10.1034/j.1399-3046.7.s3.2.x.
8
Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?
Blood. 1992 May 1;79(9):2475-9.
9
New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.镰状细胞贫血患儿接受骨髓移植时静脉注射白消安的药代动力学新见解。
Pediatr Blood Cancer. 2015 Apr;62(4):680-6. doi: 10.1002/pbc.25376. Epub 2014 Dec 31.
10
Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia.
Blood. 1994 Oct 1;84(7):2357-62.

引用本文的文献

1
Progressive Trends on the Biomedical Applications of Metal Organic Frameworks.金属有机框架材料在生物医学应用方面的进展趋势
Polymers (Basel). 2022 Nov 3;14(21):4710. doi: 10.3390/polym14214710.
2
A Review of Acute and Long-Term Neurological Complications Following Haematopoietic Stem Cell Transplant for Paediatric Acute Lymphoblastic Leukaemia.小儿急性淋巴细胞白血病造血干细胞移植后急性和长期神经并发症综述
Front Pediatr. 2021 Dec 23;9:774853. doi: 10.3389/fped.2021.774853. eCollection 2021.
3
Metal-Organic Framework Nanocarriers for Drug Delivery in Biomedical Applications.

本文引用的文献

1
Determination of busulfan in plasma by GC-MS with selected-ion monitoring.采用气相色谱-质谱联用仪选择离子监测模式测定血浆中的白消安。
J Pharm Sci. 1983 Oct;72(10):1203-5. doi: 10.1002/jps.2600721024.
2
Gas chromatographic determination of busulfan in plasma with electron-capture detection.采用电子捕获检测的气相色谱法测定血浆中的白消安。
J Chromatogr. 1983 Oct 14;277:374-80. doi: 10.1016/s0378-4347(00)84861-6.
3
Busulfan kinetics.白消安动力学
用于生物医学应用中药物递送的金属有机框架纳米载体
Nanomicro Lett. 2020 May 2;12(1):103. doi: 10.1007/s40820-020-00423-3.
4
Current and emerging therapies for primary central nervous system lymphoma.原发性中枢神经系统淋巴瘤的现有及新兴疗法。
Biomark Res. 2021 May 6;9(1):32. doi: 10.1186/s40364-021-00282-z.
5
Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population.评估模型指导的精准给药平台在儿科造血细胞移植(HCT)人群个性化白消安治疗的常规临床护理中的应用。
Front Pharmacol. 2020 Jul 2;11:888. doi: 10.3389/fphar.2020.00888. eCollection 2020.
6
Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation.比较丙戊酸和左乙拉西坦预防造血干细胞移植中白消安诱发的癫痫发作。
Int J Hematol. 2019 Jun;109(6):694-699. doi: 10.1007/s12185-019-02637-7. Epub 2019 Mar 26.
7
Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation.在接受干细胞移植的患者中,基于白消安的预处理方案在未进行预防的情况下神经毒性发生率极低。
Int J Hematol. 2016 Dec;104(6):644-646. doi: 10.1007/s12185-016-2098-8. Epub 2016 Oct 8.
8
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.高剂量利妥昔单抗联合高剂量阿糖胞苷动员疗法及高剂量噻替派、白消安和环磷酰胺自体干细胞移植治疗非霍奇金淋巴瘤累及中枢神经系统患者的2期试验
Cancer. 2015 Jan 15;121(2):226-33. doi: 10.1002/cncr.29023. Epub 2014 Sep 9.
9
Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.接受造血细胞移植的儿科和年轻成年患者中白消安的群体药代动力学:一种基于模型的给药算法,用于个性化治疗并应用于常规临床实践。
Ther Drug Monit. 2015 Apr;37(2):236-45. doi: 10.1097/FTD.0000000000000131.
10
A rapid & sensitive liquid chromatography- tandem mass spectrometry method for the quantitation of busulfan levels in plasma & application for routine therapeutic monitoring in haematopoietic stem cell transplantation.一种快速灵敏的液相色谱-串联质谱法,用于定量检测血浆中的白消安浓度,并应用于造血干细胞移植中的常规治疗监测。
Indian J Med Res. 2013 Apr;137(4):777-84.
Clin Pharmacol Ther. 1983 Jul;34(1):86-9. doi: 10.1038/clpt.1983.134.
4
Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation.白消安和全身照射作为抗造血干细胞药物,用于先天性骨髓疾病患者异基因骨髓移植的预处理。
Blood. 1984 Oct;64(4):852-7.
5
Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
Cancer Treat Rep. 1984 May;68(5):711-7.
6
Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.白消安和环磷酰胺治疗后急性非淋巴细胞白血病的骨髓移植
N Engl J Med. 1983 Dec 1;309(22):1347-53. doi: 10.1056/NEJM198312013092202.
7
Convulsions due to high-dose busulphan.大剂量白消安引起的惊厥
Lancet. 1984 Dec 22;2(8417-8418):1463. doi: 10.1016/s0140-6736(84)91649-0.
8
Pharmacokinetics of high-dose melphalan in children and adults.高剂量美法仑在儿童和成人中的药代动力学。
Cancer Chemother Pharmacol. 1986;16(2):184-9. doi: 10.1007/BF00256174.
9
Pretransplant conditioning with busulfan (Myleran) and cyclophosphamide for nonmalignant diseases. Assessment of engraftment following histocompatible allogeneic bone marrow transplantation.使用白消安(马利兰)和环磷酰胺对非恶性疾病进行移植前预处理。评估组织相容性同种异体骨髓移植后的植入情况。
Transplantation. 1985 Jun;39(6):597-603. doi: 10.1097/00007890-198506000-00004.
10
Recent advances in the use of stable isotopes in drug metabolism research.稳定同位素在药物代谢研究中的最新进展。
J Clin Pharmacol. 1986 Jul-Aug;26(6):481-4. doi: 10.1002/j.1552-4604.1986.tb03562.x.